SEC Form 4 · accession 0001209191-17-065191
COLLEGIUM PHARMACEUTICAL, INC · COLL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Patrick G Enright
10% Owner
Longitude Venture Partners L.P.
10% Owner
Longitude Capital Associates, L.P.
10% Owner
Longitude Capital Partners, LLC
10% Owner
Bakker Juliet Tammenoms
10% Owner
Period of report
Dec 8, 2017
Accepted (ET)
Dec 12, 2017 · 4:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 8, 2017 | S | 980,350 | $17.34 | D | 2,276,222 | I | By LVP |
| Common StockF1 | Dec 8, 2017 | S | 19,650 | $17.34 | D | 45,620 | I | By LCA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.